For the first time, the effectiveness of a womb cancer drug in clinical trials has surprised everyone. Dostarlimab, the drug, appears to have cured all of the trial participants. A small group of patients suffering from rectal cancer saw their cancer disappear after undergoing the experimental treatment. According to reports, the 18 patients in the small clinical trial took Dostarlimab for around six months and after over 12 months the doctors found that their cancer has disappeared.
According to experts, Dostarlimab is a drug made in a lab that acts as a substitute for antibodies in the human body. Reportedly all 18 rectal cancer patients were given the same drug and as a result of the treatment, cancer was completely obliterated in every patient. The cancer is undetectable by physical exam; endoscopies, positron emission tomography (PET) scans, and magnetic resonance imaging (MRI) scans are all ineffective in detecting the malignancy.
Although the trial’s sample size is limited, it clearly shows that Dostarlimab has the potential to cure one of the most deadly cancers. Dr. Luis A. Diaz J. of New York’s Memorial Sloan Kettering Cancer Center said this was “the first time this has happened in the history of cancer”.According to reports, the patients involved in the clinical trial earlier underwent treatments such as chemotherapy, radiation, and invasive surgery that could result in bowel, urinary, and even sexual dysfunction. Moreover, the 18 patients went into the trial expecting to have to go through these as the next step. However, they were surprised to learn that no more therapy was required.
Several experts have hailed the research as a world-first and highlighted that it is more impressive as not all of the patients suffered significant complications from the trial drug. The patients were given Dostarlimab every three weeks for six months during the experiment. All patients were in similar stages of their cancer. The cancer was locally advanced in the rectum but had not spread to other organs.
In a report published in the New England Journal of Medicine on Sunday, researchers wrote: No patients had received chemoradiotherapy or surgery at the time of this report, and no cases of progression or recurrence had been recorded during follow-up. However, a larger-scale trial is needed to see if it will work for more patients and if the cancers are truly in remission.